Last reviewed · How we verify
NCT03988582
Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies
Phase 2 trial testing EBV-specific T-cells in EBV Lymphomas. Withdrawn.
8 June 2020
Quick facts
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 11 June 2019 |
| Primary completion | 8 June 2020 |
| Estimated completion | 8 June 2020 |
Drugs / interventions tested
- EBV-specific T-cells — full drug profile →
Conditions studied
- EBV Lymphomas — all drugs for EBV Lymphomas →
- EBV-associated Malignancies — all drugs for EBV-associated Malignancies →
Sponsor
Memorial Sloan Kettering Cancer Center — full company profile →
Who can join
Eligibility, any sex, with EBV Lymphomas or EBV-associated Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to test whether treatment with EBV-specific cytotoxic T cells (EBV-CTLs) is effective, and to test any good and bad effects of treatment with EBV-CTLs. EBV-CTLs are a special immune cells that may attack abnormal cells. EBV-CTLs are made by taking cells from a healthy person, growing them in a laboratory for several weeks to educate them to recognize and destroy EBV infected cells, and then storing them in a freezer until they are required for treatment.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.
Cao Y, Xie L, Shi F, Tang M, et al · · 2021 · cited 86× · PMID 33436584 · DOI 10.1038/s41392-020-00376-4 -
Virus-specific T cells for malignancies - then, now and where to?
Sharma S, Leung WK, Heslop HE. · · 2020 · cited 6× · PMID 33738181 · DOI 10.1007/s40778-020-00170-6
Verify or expand the search:
- PubMed search for NCT03988582
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Memorial Sloan Kettering Cancer Center trials
Trials by the same sponsor.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
- NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
- NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
- NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03988582 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
- Last refreshed: 11 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03988582.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing